{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T17:52:12Z","timestamp":1782150732348,"version":"3.54.5"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"DOI":"10.7759\/cureus.91435","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T21:28:04Z","timestamp":1756762084000},"source":"Crossref","is-referenced-by-count":1,"title":["Levetiracetam-Induced Rhabdomyolysis: An Alarming and Unexpected Turn in Seizure Management"],"prefix":"10.7759","author":[{"given":"Usamah","family":"Al-Anbagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad E","family":"Alharafsheh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassem","family":"Al Hariri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Memon","family":"Noor Illahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulqadir  J","family":"Nashwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Sharif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000546","article-title":"Therapeutic drug monitoring of antiepileptic drugs in epilepsy: A 2018 update","volume":"40","author":"Patsalos PN","year":"2018","unstructured":"Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: A 2018 update. Ther Drug Monit. 2018, 40:526-48. 10.1097\/FTD.0000000000000546","journal-title":"Ther Drug Monit"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.30042","article-title":"Levetiracetam-induced rhabdomyolysis following medication re-initiation","volume":"14","author":"Boucher KS","year":"2022","unstructured":"Boucher KS, Dedhia N, Bommisetty D. Levetiracetam-induced rhabdomyolysis following medication re-initiation. Cureus. 2022, 14:e30042. 10.7759\/cureus.30042","journal-title":"Cureus"},{"key":"ref3","article-title":"Rhabdomyolysis: pathogenesis, diagnosis, and treatment","volume":"15","author":"Torres PA","year":"2015","unstructured":"Torres PA, Helmstetter JA, Kaye AM, Kaye AD. Rhabdomyolysis: pathogenesis, diagnosis, and treatment. Ochsner J. 2015, 15:58-69.","journal-title":"Ochsner J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0801327","article-title":"Rhabdomyolysis and acute kidney injury","volume":"361","author":"Bosch X","year":"2009","unstructured":"Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. N Engl J Med. 2009, 361:62-72. 10.1056\/NEJMra0801327","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/cc2978","article-title":"Bench-to-bedside review: Rhabdomyolysis -- an overview for clinicians","volume":"9","author":"Huerta-Alard\u00edn AL","year":"2005","unstructured":"Huerta-Alard\u00edn AL, Varon J, Marik PE. Bench-to-bedside review: Rhabdomyolysis -- an overview for clinicians. Crit Care. 2005, 9:158-69. 10.1186\/cc2978","journal-title":"Crit Care"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.48955","article-title":"Levetiracetam-induced rhabdomyolysis reversed by discontinuation: a case report","volume":"15","author":"Kazmi JS","year":"2023","unstructured":"Kazmi JS, Albarghouthy N, Ramsaywak R. Levetiracetam-induced rhabdomyolysis reversed by discontinuation: a case report. Cureus. 2023, 15:e48955. 10.7759\/cureus.48955","journal-title":"Cureus"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/1234738","article-title":"Rhabdomyolysis induced by levetiracetam: a case report in Kuwait","volume":"2024","author":"Qureshi M","year":"2024","unstructured":"Qureshi M, Abraham PA, Al-Faras A, Bamasood OM, Matar KM. Rhabdomyolysis induced by levetiracetam: a case report in Kuwait. Case Rep Neurol Med. 2024, 2024:1234738. 10.1155\/2024\/1234738","journal-title":"Case Rep Neurol Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-230851","article-title":"Rhabdomyolysis: a rare adverse effect of levetiracetam","volume":"12","author":"Thomas L","year":"2019","unstructured":"Thomas L, Mirza MM, Shaikh NA, Ahmed N. Rhabdomyolysis: a rare adverse effect of levetiracetam. BMJ Case Rep. 2019, 12:10.1136\/bcr-2019-230851","journal-title":"BMJ Case Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.926064","article-title":"Suspected levetiracetam-induced rhabdomyolysis: a case report and literature review","volume":"21","author":"Moinuddin IA","year":"2020","unstructured":"Moinuddin IA. Suspected levetiracetam-induced rhabdomyolysis: a case report and literature review. Am J Case Rep. 2020, 21:e926064. 10.12659\/AJCR.926064","journal-title":"Am J Case Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam","volume":"101","author":"Lynch BA","year":"2004","unstructured":"Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A. 2004, 101:9861-6. 10.1073\/pnas.0308208101","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.80877","article-title":"Two cases of levetiracetam-induced rhabdomyolysis with low levetiracetam blood concentrations","volume":"17","author":"Kodama K","year":"2025","unstructured":"Kodama K, Imai T, Kuwana T, Ootsuka S, Kinoshita K. Two cases of levetiracetam-induced rhabdomyolysis with low levetiracetam blood concentrations. Cureus. 2025, 17:e80877. 10.7759\/cureus.80877","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/405593-levetiracetam-induced-rhabdomyolysis-an-alarming-and-unexpected-turn-in-seizure-management","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T21:28:05Z","timestamp":1756762085000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/405593-levetiracetam-induced-rhabdomyolysis-an-alarming-and-unexpected-turn-in-seizure-management"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.91435","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}